卫信康(603676) - 卫信康投资者关系活动记录表

Group 1: Company Overview - The company is Xizang Weixin Kang Pharmaceutical Co., Ltd. with stock code 603676 [1] - The company held investor relations activities in September 2023, including strategy meetings with various securities and asset management firms [2] Group 2: Sales Performance - Revenue from the injection of multiple vitamins (12) reached approximately 542.62 million yuan, accounting for 72.41% of the company's total revenue [3] - The sales from the alliance region in Henan province contributed about 30.08% to the company's total revenue [3] Group 3: Market Strategy and Coverage - As of June 2023, the injection of multiple vitamins (12) was covered in over 2,400 hospitals, primarily in secondary and tertiary hospitals [3] - The company plans to enhance market share through reasonable market strategies despite a decrease in the winning price compared to the original benchmark price [3] Group 4: Product Development and Future Opportunities - The company has recently approved potential products, including pediatric compound amino acid injection (19AA-I) and other electrolyte solutions, which are expected to contribute to revenue growth [3] - The concept of nutritional therapy is evolving, indicating a promising long-term development trajectory for the industry [4]